Actualités id6369.html
In consultation: Guidance and quality standards
Sun, 02 Oct 2022 14:12:00 GMT
Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [ID6369] Draft guidance Technology appraisal guidance 2 April ...